A negative HPV test may predict lower cervical cancer risk than a negative Pap

July 19, 2014, Oxford University Press

In the US, cotesting for human papilloma virus (HPV) and Pap testing for cervical cancer every 5 years for women aged 30-65 years is now recommended. However, HPV testing alone may provide better reassurance against cervical cancer than Pap testing alone and similar reassurance to cotesting, according to a study published July 18 in the Journal of the National Cancer Institute.

In a comparison of the three strategies, Julia C. Gage, Ph.D., M.P.H., of the Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, MD, and colleagues analyzed data from the Kaiser Permanente Northern California (KPNC) large integrated health delivery system, which screened women age 30-64 since 2003 with both HPV and Pap testing. Data were available through 2012, and over 1 million women were screened at approximately 3-year intervals, with a mean follow-up time of 4.36 years. For each testing strategy, they estimated the cumulative risk of after a negative test result.

The researchers found that the 3-year cancer risks after a negative HPV-alone test result were lower than those for a Pap-alone negative result. In addition, the 3-year cancer risks after a negative HPV-alone test result were similar to the 5-year cancer risk for a co-test negative result. Gage et al. write "In conclusion, we find that primary HPV testing every 3 years might provide as much, if not more, reassurance against precancer and cancer, compared to primary Pap testing every 3 years and cotesting every 5 years." However, the authors note that a screening program based on only one or the other test alone, rather than a cotesting program like that at KPNC, might give somewhat different estimates. They urge studies of screening programs in different health-care settings and populations to identify the optimal screening strategy and interval.

In an accompanying editorial, Jane J. Kim, of the Harvard School of Public Health, Department of Health Policy and Management, Center for Health Decision Science, Boston, MA, also cautions that the data reflect management based on cotesting and notes that the HPV test approved for primary screening specifically assays the two highest-risk HPV types (16 and 18) that account for 70% of cervical cancers but pools the assay for the other 12 HPV strains. However, despite these caveats, Dr. Kim concludes that the authors "…provide timely evidence from the United States that HPV primary testing can provide equal or more reassurance against risk than strategies currently recommended by guidelines."

Explore further: What's the best test for cervical cancer? Pap, HPV or both?

Related Stories

What's the best test for cervical cancer? Pap, HPV or both?

June 9, 2014
Should U.S. women be screened for cervical cancer with Pap tests, HPV tests or both? According to researchers from Boston University School of Medicine (BUSM) and Boston Medical Center (BMC) while the merits of screening ...

HPV testing: IQWiG still sees indications of a benefit in primary screening

June 11, 2014
The Institute for Quality and Efficiency in Health Care (IQWiG) assessed current study results on the benefit of a test for human papillomavirus (HPV) and examined whether its first assessment from January 2012 is still valid. ...

FDA experts debate timing of pap test

March 12, 2014
(HealthDay)—The Pap test has been a routine gynecological procedure for generations of American women. But on Wednesday, a Food and Drug Administration advisory panel is considering whether to delay the Pap test and use ...

Longer screening intervals possible with HPV-based tests

January 21, 2014
A new study from Karolinska Institutet in Sweden finds that testing for human papilloma virus (HPV) allows for longer time between screening tests when compared to cytology-based testing. The study is published in the scientific ...

Female doctors twice as likely to screen low-risk women for cervical cancer with HPV test

November 7, 2013
For low-risk women, the likelihood that they get tested for the infection that causes cervical cancer (human papillomavirus or HPV) may depend on what clinic they visit, their doctor's status and whether their provider is ...

HPV testing could cut cervical cancers by a third

June 14, 2013
(Medical Xpress)—Testing women for the human papillomavirus (HPV) first, instead of using the traditional cervical screening test to detect abnormal cells in the cervix, could prevent around 600 cases of cervical cancer ...

Recommended for you

Single-cell study in a childhood brain tumor affirms the importance of context

April 20, 2018
In defining the cellular context of diffuse midline gliomas, researchers find the cells fueling their growth and suggest a potential approach to treating them: forcing their cells to be more mature.

Aggressive breast cancer already has resistant tumour cells prior to chemotherapy

April 20, 2018
Difficult to treat and aggressive "triple-negative" breast cancer is chemoresistant even before chemotherapy begins, a new study by researchers from Karolinska Institutet and the University of Texas MD Anderson Cancer Center ...

Mechanism that drives development of liver cancer brought on by non-alcoholic fatty liver disease discovered

April 19, 2018
A team of researchers from several institutions in China has found a mechanism that appears to drive the development of a type of liver cancer not caused by alcohol consumption. In their paper published in the journal Science ...

Discovery adds to evidence that some children are predisposed to develop leukemia

April 19, 2018
St. Jude Children's Research Hospital researchers have made a discovery that expands the list of genes to include when screening individuals for possible increased susceptibility to childhood leukemia. The finding is reported ...

Scientists identify 170 potential lung cancer drug targets using unique cellular library

April 19, 2018
After testing more than 200,000 chemical compounds, UT Southwestern's Simmons Cancer Center researchers have identified 170 chemicals that are potential candidates for development into drug therapies for lung cancer.

Chip-based blood test for multiple myeloma could make bone biopsies a relic of the past

April 19, 2018
The diagnosis and treatment of multiple myeloma, a cancer affecting plasma cells, traditionally forces patients to suffer through a painful bone biopsy. During that procedure, doctors insert a bone-biopsy needle through an ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.